Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles
Stretch Mark Cream

Women At Risk Of Gaining Excessive Weight With Injectable Birth Control Identified By UTMB Study
Researchers at the University of Texas Medical Branch at Galveston have identified women who are likely to gain weight while using depot medroxyprogesterone acetate, more commonly known as Depo-Provera or the birth control shot. These findings dispel the myth that all women who use DMPA will gain weight and will help physicians to counsel patients appropriately.
generic viagra online
The Ozone Man Treats Xaverian High School To Prevent Spread Of Contaminated Swine Flu Within Its Indoor Environments
The Ozone Man, Inc. (OTCBB: OZOM), dba TOMI Environmental Solutions, or TOMIES, announced today the completion of a deep cleaning treatment of Xaverian High School with a student body of 1400 located in Brooklyn, New York. The Ozone Man"s treatment eliminated contaminants including Swine Flu "H1N1" along with inactivating viruses. The Ozone Man"s treatment also eliminates odor, mold spores and kills bacteria in the treated areas. Its proprietary Ultraviolet Ozone Generators produce the cleanest ozone south of the stratosphere, helping to ensure the health, safety and well being of the building and its inhabitants. Drugshop to buy zoloft online and other pills.
News of the day
National Organization For Rare Disorders To Honor Rare Disease Pioneers
The National Organization for Rare Disorders (NORD) will honor a senior U.S. Senator, a top Administration official, a cutting-edge television network, and several pioneering companies developing treatments for rare diseases at the 2009 NORD Gala at the National Press Club in Washington, DC, on Thursday, May 14.
Oncology

Institute For Oneworld Health Announces Successful Collaboration To Fight Neglected Diarrheal Diseases In Developing Countries

The Institute for OneWorld Health, the US-based non-profit pharmaceutical company that develops drugs for people with neglected infectious diseases in the developing world, today announced that it has successfully completed its first screening campaign of the Roche proprietary compound library and will select up to 40 new drug leads for further study intended to identify a new treatment for childhood diarrhea. OneWorld Health and Roche, a multinational pharmaceutical company with headquarters in Basel, Switzerland, and a global research presence, entered into a research collaboration in the spring of 2008 to fight neglected diarrheal diseases, which kill nearly two million children under the age of five in the developing world each year. "Our work with Roche is an example of the different kinds of partnerships required to make the goal of reducing childhood deaths from diarrheal diseases in the developing world a reality," said Dr. Richard Chin, OneWorld Health"s Chief Executive Officer. "The world has shown its resolve to fight pediatric diarrheal diseases by committing to the UN Millennium Development Goal of reducing the child mortality rate by two-thirds by 2015." OneWorld Health is a member of a coalition of more than 75 organizations (http://www.eddcontrol.org/call-to-action.php ) calling for action by the international community to stop needless deaths caused by diarrheal diseases. The coalition yesterday released two vital reports outlining the approaches and res necessary to stem the tide of diarrheal deaths at a high-level forum in Washington, DC, convened by PATH and WaterAid America. Diarrheal diseases-cholera, rotavirus, shigellosis, and others-are the second leading killer of children under the age of five in the developing world. OneWorld Health is working with its partners to discover and develop novel anti-secretory diarrheal drugs that will reduce fluid loss and help prevent death from dehydration caused by acute watery diarrheal diseases. This treatment is intended to be used as an adjunct to Oral Rehydration Therapy and zinc to save the lives of infants and children. OneWorld Health commissioned BioFocus DPI to perform high-throughput screening of more than 780,000 molecules from Roche"s compound library in search of potential leads for its diarrheal diseases program, and will follow up on these leads to assemble a portfolio of drug candidates that address various aspects of diarrheal diseases. Institute for OneWorld Health and Roche


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009